Seer Enters into A Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Market Closed – Nasdaq			5-day change	1st Jan Change
2.380 ^USD	+7.21%		+25.26%	+22.68%

November 06, 2024 at 04:03 pm EST

Seer, Inc. announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer?s Proteograph Product Suite alongside Thermo Scientific Orbitrap Astral? mass spectrometers. This strategic collaboration aims to accelerate the adoption of innovative proteomic technologies, offering researchers an integrated solution for deep, rapid, and unbiased proteomic analysis at scale. Under this non-exclusive agreement, Thermo Fisher?s global sales force will have the ability to quote and sell Seer?s Proteograph Product Suite, which includes an automation instrument, proprietary engineered nanoparticles, and software analysis suite, enhancing the accessibility of this innovative technology to life science researchers worldwide. The integration is set to commence in early 2025, further expanding the reach of Seer?s platform. The collaboration will also enable Seer and Thermo Fisher to conduct joint marketing activities,
including conference promotions, seminars, and webinars, to showcase the combined power of their proteomic
platforms. The companies will work together to improve workflows, creating a seamless sample-to-data experience that integrates the Proteograph and Astral technologies. The combination of the Proteograph Product Suite and Orbitrap Astral has generated exciting data for academic and commercial customers. Seer and Thermo Fisher plan to collaborate on additional joint research studies, including population scale studies, to demonstrate the comprehensive capabilities of their combined platforms, further solidifying their commitment to advancing the field of proteomics.

Earnings Flash (SEER) SEER Reports Q3 Revenue $4M	Nov. 06	MT
Seer, Inc., Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Seer, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Seer Enters into A Co-Marketing and Sales Agreement with Thermo Fisher Scientific	Nov. 06	CI
Seer, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 04:05 PM	Sep. 05
PrognomiQ, Inc. announced that it has received $34.315382 million in funding from Seer, Inc., Catalio Capital Management, LP, aMoon Fund, The Invus Group, LLC, Bruker Corporation and other investors	Aug. 25	CI
Seer, Inc. Appoints Nicolas Roelofs to Its Board of Directors	Aug. 14	CI
PrognomiQ, Inc. announced that it expects to receive $52.786374 million in funding	Aug. 08	CI
Earnings Flash (SEER) SEER Posts Q2 Revenue $3.1M, vs. Street Est of $3M	Aug. 08	MT
Seer, Inc., Q2 2024 Earnings Call, Aug 08, 2024	Aug. 08
Tranche Update on Seer, Inc.’s Equity Buyback Plan announced on May 8, 2024.	Aug. 08	CI
Seer, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 08	CI
Seer, Inc. Revises Revenue Guidance for the Full Year 2024	Aug. 08	CI
Terns Pharmaceuticals Names Elona Kogan as Chief Legal Officer; CFO Mark Vignola to Leave in ‘Planned Transition’	Jul. 30	MT
Seer, Inc. Announces Executive and Committee Changes	Jul. 19	CI
Seer, Inc. Announces Resignation of Rachel Haurwitz as Board of Directors and All Committees	Jul. 12	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 3000 Value Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 2000 Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 3000E Value Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 3000E Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 2500 Value Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 2000 Value Index	Jun. 30	CI
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 2000 Dynamic Index	Jun. 30	CI

Duration

Period

SEER: Dynamic Chart

Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.

More about the company

Sell